IGF1 and prostate cancer: In prostate cancer patients, Johansson et al. demonstrated that heterozygous haplotype of T-C-C (rs6220-rs7136446-rs2033178 [GenBank]) in the 3′ region of the IGF-1, which was a risk haplotype of prostate cancer risk in their previous study, was significantly associated with higher circulating levels of IGF-1 [27].